Hand using a tablet with digital document approval icons

Integrated Summary of Safety – Complexities, Communication and Completion

1 minute read

Published: January 25th, 2021

Phastar was contracted to assist a pharmaceutical company with the conversion of 16 legacy studies to SDTM (2 SDTM “Like” phase II studies, 14 Legacy Phase I studies) and with the pooling and reporting activities of their Integrated Summary of Safety (ISS) for a regulatory submission. It has been quite a challenging project but one of the most exciting due to its complexity.

Complete the form below to read the full case study

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

November 16th, 2026 1 minute read

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful developme...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...